Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
Tóm tắt
Từ khóa
Tài liệu tham khảo
Londin E, Loher P, Telonis AG et al (2015) Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. PNAS 23:E1106–E1115Epub February
Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6:259–269
Kasinski AL, Slack FJ (2011) MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11:849–864
Bader AG (2012) miR-34–a microRNA replacement therapy is headed to the clinic. Front Genet 3: article 120
Cortez MA, Ivan C, Valdecanas D, Wang X et al (2016) PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 108:djv303
Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement therapy. Cancer Res 70:7027–7030
Trang P, Wiggins JF, Daige DL et al (2011) Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19:1116–1122
Bader AG, Brown D, Stoudemire J et al (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18:1121–1126
Daige CL, Wiggins JF, Priddy L et al (2014) Systemic delivery of a miR-34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther 13:2352–2360
Kelnar K, Peltier HJ, Leatherbury N et al (2014) Quantification of therapeutic miRNA mimics in whole blood from non-human primates. Anal Chem 86:1534–1542
He L, He X, Lim LP et al (2007) A microRNA component of the p53 tumor suppressor network. Nature 447:1130–1134
Zhao J, Lammers P, Torrance CJ et al (2013) TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1). Mol Ther 21:678–686
Lee CH, Subramanian S, Beck AH et al (2009) MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. PLoS One 4:e7314
Hagman Z, Larne O, Edsjo A et al (2010) miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127:2768–2776
Nakatani F, Ferracin M, Manara MC et al (2012) miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226:796–805
Jamieson NB, Morran DC, Morton JP et al (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18:534–545
Hiyoshi Y, Schetter AJ, Okayam H et al (2015) Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer. PLoS One 10:e0124899
Wang J, Dan G, Zhao J et al (2015) The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis. Onco Targets Ther 8:2709–2719
Shin J, Danli X, Zhong XP (2013) MicroRNA-34a enhances T cell activation by targeting Diacylglycerol kinase ζ. PLoS One 8:e77983
Cortez MA, Valdecanas D, Niknam S et al (2015) In vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation. Molecular Therapy—Nucleic Acids 4:e270
Wang X, Li J, Dong K et al (2015) Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal 27(3):443–452
Ji Q, Hao X, Zhang M et al (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4:e6816
Li N, Fu H, Tie Y et al (2009) miR-34a inhibits migration and invasion by down-regulation of c-met expression in human hepatocellular carcinoma cells. Cancer Lett 275:44–53
Liu C, Kelnar K, Liu B et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17:211–215
Di Martino MT, Leone E, Amodio N et al (2012) Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 18:6260–6270
Zhao J, Kelnar K, Bader AG (2014) In-depth analysis shows synergy between erlotinib and miR-34a. PLOS One Feb 14:e8910
Wiggins JF, Ruffino L, Kelnar K et al (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70:5923–5930
Craig VJ, Tzankov A, Flori M et al (2012) Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia 26:2421–2424
Tolcher AW, Rodrigueza WV, Rasco DW et al (2014) A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol 73:363–371
Kelnar K , Bader, AB (2015) A qRT-PCR method for determining the biodistribution profile of a miR-34a mimic. Chapter 8. In: Gene therapy of solid cancers: methods and protocols, Methods in Molecular Biology, Walther W, Stein U, eds 1317:125–33
Szebeni J, Muggia F, Gabizon A et al (2011) Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63:1020–1030
Robbins M, Judge A, Ambegia E et al (2008) Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19:991–999
Chattopadhyay S (2014) Sen GC: dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects. J Interf Cytokine Res 34(6):427–436
Chiappinelli KB, Strissel PL, Desrichard A et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162:974–986